News Agency
Men's Weekly

Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023

  • Written by PR Newswire

HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid leukemia (AML) at the 65th American Society of...

Read more: Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly...

Improving Internal Feedback Loops Through CMS-Based Commenting and Versioning

Collaboration is essential for successful digital content creation. Unfortunately, in many companies, the feedback mechanism between marketing, design, product and development functions is less than cohesive. For example, feedback is left in email chains, instant chat messages, or within locked... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion